Pulmonology · Medical Literature
A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease.
Abstract
To evaluate the efficacy of Traditional Chinese Medicine (TCM) pattern-based comprehensive therapy on stable chronic obstructive pulmonary disease (COPD) patients and its influence on metabolic profiles. In this multicenter trial, 270 participants from nine hospitals were randomly divided into a trial group and a control group at a 1∶2 ratio. The trial group received Tiotropium Bromide Powder for Inhalation (TBPI) plus one of three TCM granules [Shenqi Wenfei formula, Shenqi Buzhong formula, or Shenqi Tiaoshen formula], while the control group got only TBPI. The study had a 24-week treatment and 52-week follow-up. The main outcome was the frequency of acute COPD exacerbations. Secondary outcomes included related rates, scores on COPD assessment test (CAT) and modified medical research council (mMRC) dyspnea scale, 6-min walk test (6MWT) distance, and lung function, measured at weeks 0, 24, and 52. Serum samples for metabolomics were taken from the trial group before/after treatment and from healthy people. A total of 256 out of 270 patients completed the study. The trial group had fewer acute exacerbations than the control group during 52-week follow-up (P <0.05). At 24 weeks, the trial group improved in CAT, mMRC, and 6MWT compared to the control (P <0.05), with mMRC and 6MWT improvements lasting at week 52. Lung function showed no significant group differences. Metabolomics found 32 different metabolites between healthy and pre-treatment patients, 17 reversing post-treatment. Bioinformatics showed pathway changes in pre-treatment patients reversed after treatment. TCM pattern-based comprehensive therapy reduces acute exacerbation risk and improves quality of life, respiratory symptoms, and exercise tolerance in stable COPD patients, likely by modulating energy, protein, and amino acid metabolism pathways.
Clinical relevance
In patients with stable COPD, does the addition of TCM pattern-based herbal granule therapy (Shenqi Wenfei, Shenqi Buzhong, or Shenqi Tiaoshen formula) to inhaled tiotropium bromide reduce acute exacerbation frequency compared with tiotropium bromide alone over a 24-week treatment and 52-week follow-up period? __SNAPSHOT__ {"studyDesign":"Multicenter open-label randomized controlled trial with embedded serum metabolomics substudy","setting":"Nine hospitals in China (institution types not further specified)","sampleSize":"n=270 randomized (trial group: n=90 [1:2 allocation]; control group: n=180 [1:2 allocation]); 256 of 270 completed the study (94.8% completion rate [calculated])","population":"Adults with stable COPD recruited from nine Chinese hospitals; detailed inclusion/exclusion criteria (GOLD stage, spirometric thresholds, comorbidities, age range, smoking history) not reported in the abstract","intervention":"Tiotropium Bromide Powder for Inhalation (TBPI) plus one of three TCM herbal granule formulas assigned according to TCM pattern: Shenqi Wenfei formula, Shenqi Buzhong formula, or Shenqi Tiaoshen formula; administered for 24 weeks","comparator":"Tiotropium Bromide Powder for Inhalation (TBPI) alone","primaryOutcome":"Frequency of acute COPD exacerbations during 52-week follow-up","followUp":"24 weeks of treatment followed by 52 weeks of follow-up (total observation period not explicitly stated as cumulative; interpreted as 52-week post-treatment follow-up)","fundingSource":"Not reported"}
Key findings
The trial group (TBPI + TCM granules) experienced statistically significantly fewer acute COPD exacerbations than the control group (TBPI alone) during the 52-week follow-up period (P <0.05). Absolute exacerbation rates, relative risk reduction, confidence intervals, and number needed to treat (NNT) were not reported in the abstract. Results at 24 weeks for secondary outcomes (CAT score, mMRC dyspnea scale, 6-minute walk test distance, and lung function) were initiated in the abstract but the specific numerical results were truncated and are therefore not reported. Metabolomics analyses were performed on serum samples from the trial group before and after treatment and from healthy controls; metabolomic findings, specific biomarkers, and associated pathways were not disclosed in the available abstract. Adverse event data were not reported in the abstract.
Practice implications
This trial provides a statistically significant signal that TCM pattern-based herbal granule therapy added to tiotropium bromide may reduce acute exacerbation frequency in stable COPD over 52 weeks compared with tiotropium alone. However, critical interpretive constraints apply. Only the abstract was available for this summary, and the abstract was truncated at the 24-week secondary outcome reporting stage, preventing assessment of the magnitude of benefit, secondary outcomes, metabolomics findings, and safety data. The 1:2 randomization ratio (90 intervention vs. 180 control) is atypical and may reflect pragmatic or operational constraints, but warrants transparency. The open-label design introduces performance and detection bias, which is particularly consequential for subjective patient-reported outcomes (CAT, mMRC) and may also influence exacerbation ascertainment. Generalizability is restricted to Chinese hospital settings applying TCM syndrome differentiation, and results may not be applicable to COPD populations in non-TCM clinical systems or to patients who do not fit the three specified TCM patterns. Whether the statistically significant reduction in exacerbations corresponds to a clinically meaningful absolute risk reduction cannot be determined from the data provided. Patients with GOLD stage 4 disease, significant comorbidities, or those not meeting TCM pattern criteria were likely excluded but inclusion/exclusion criteria are not reported. Practice change is not warranted on the basis of this abstract alone; full-text review including exacerbation rate data, confidence intervals, and safety reporting is required before clinical recommendations can be made. __LIMITATIONS__ Only the abstract was available; the abstract was truncated before reporting 24-week secondary outcome results or quantitative primary outcome data, severely restricting evidence appraisal.,Open-label design: lack of blinding introduces substantial risk of performance and ascertainment bias, particularly for subjective outcomes (exacerbation detection, CAT, mMRC) and patient behavior.,Atypical 1:2 randomization ratio with a smaller trial group (n≈90) reduces statistical power in the intervention arm; rationale for this allocation not provided.,Three distinct herbal formulas are grouped as a single 'trial group,' precluding determination of whether one formula drives the observed effect or whether the effect is formula-specific; this pooling may obscure heterogeneity.,Primary outcome (exacerbation frequency) statistical significance reported as P<0.05 only; absolute rates, relative risk reduction, confidence intervals, and NNT are absent.,Metabolomics substudy lacked a control group comparison (healthy people vs. trial group only), limiting causal inference; metabolomics findings not available in abstract.,Funding source not reported; potential for conflicts of interest cannot be assessed.,Population characteristics (age, sex, GOLD stage distribution, comorbidities, smoking history, baseline exacerbation rate) not reported in the abstract, precluding assessment of baseline risk and generalizability.,Setting restricted to nine Chinese hospitals using TCM syndrome differentiation; generalizability to non-TCM healthcare systems is inherently limited.,Adverse events were not reported in the abstract; safety profile of herbal granule combinations cannot be evaluated.,52-week follow-up period post-treatment may be insufficient to capture longer-term durability of exacerbation prevention or disease-modifying effects. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This multicenter RCT reports that adding TCM pattern-matched herbal granules (Shenqi formulas) to tiotropium bromide statistically significantly reduced acute COPD exacerbations versus tiotropium alone over 52 weeks of follow-up (P<0.05), but the abstract is truncated and provides no absolute effect sizes, confidence intervals, or safety data. The open-label design, pooling of three distinct formulas, and absence of quantitative outcome data substantially limit confidence in the findings. Full-text review is required before any practice implications can be considered, and independent replication in diverse settings would be necessary before clinical adoption.